Medtronic initiated with an Equal Weight at Barclays
Barclays initiated Medtronic (MDT) with an Equal Weight rating and $95 price target, citing attractive multiples and expected 2027 fundamentals. The firm's top picks include Edwards Lifesciences, Stryker, Beta Bionics, DexCom, and LivaNova. Archer Aviation (ACHR) and SpaceX (SPCX) have Strong Buy consensus, with ACHR showing more upside potential. Cathie Wood's ARK Invest bought 2.57M ACHR shares and sold 54,873 SPCX shares. ACHR is down 38% YTD but has a $11.60 avg.
How this was made
The 30-second read
Why it matters
The new rating and target could attract fresh buying, especially from value‑focused investors.
Market read
First analyst coverage of Medtronic provides fresh valuation insight, potentially influencing short‑term price action.
What to watch
Potential competition and upcoming regulatory scrutiny could temper upside.
Background
Barclays launched its coverage of Medtronic, a leading medical device maker, citing sector underperformance as a buying opportunity.
Ticker impact
Barclays initiated coverage of Medtronic with an Equal Weight rating and a $95 price target.
likely upward pressure as investors price in the new target
First coverage from a major bank often triggers buying interest, especially with a target above market price.
Market effects
May boost sentiment for the broader medical devices sector as coverage expands.
Limited to U.S. equities; no broader regional effect.
Low; impact confined to Medtronic and peers.
Counterpoint
Investors may view the target as overly optimistic if current fundamentals are weak.
Key entities
- AnalystBarclays
Equity research firm initiating coverage.
- CompanyMedtronic
Medical devices and supplies manufacturer.
